Fallopian Tube Endometrioid Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Endometrioid Adenocarcinoma:

Name: Fallopian Tube Endometrioid Adenocarcinoma ¹² ¹⁵ ⁷⁰

Endometrioid Carcinoma of the Fallopian Tube ¹²

Fallopian Tube Endometrioid Neoplasm ¹²

Fallopian Tube Endometrioid Cancer ¹²

Fallopian Tube Endometrioid Tumor ⁷⁰

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:5831

NCIt ⁵⁰ C40111 C6279

UMLS ⁷⁰ C1333592 C1517113

Sources

Summaries for Fallopian Tube Endometrioid Adenocarcinoma

Disease Ontology : ¹² A fallopian tube adenocarcinoma that derives from endometrial epithelial cells of glandular origin.

MalaCards based summary : Fallopian Tube Endometrioid Adenocarcinoma, also known as endometrioid carcinoma of the fallopian tube, is related to fallopian tube carcinoma and serous cystadenocarcinoma. An important gene associated with Fallopian Tube Endometrioid Adenocarcinoma is CALB2 (Calbindin 2), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Paclitaxel and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, and related phenotypes are cellular and embryo

Sources

Related Diseases for Fallopian Tube Endometrioid Adenocarcinoma

Diseases related to Fallopian Tube Endometrioid Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)

#	Related Disease	Score	Top Affiliating Genes
1	fallopian tube carcinoma	30.3	RAD51C PAX8 ERBB2
2	serous cystadenocarcinoma	29.9	PAX8 MUC16 ERBB2 ARID1A
3	female reproductive endometrioid cancer	29.0	PMS2 PAX8 MSH6 ERBB2 ARID1A
4	cervical carcinosarcoma	10.4	MME CALB2
5	pacinian tumor	10.4	MME CALB2
6	malignant glandular tumor of peripheral nerve sheath	10.4	MYOG CALB2
7	lung combined type small cell carcinoma	10.4	MYOG MME
8	heart lymphoma	10.4	MYOG MME
9	pseudo-meigs syndrome	10.4	MUC16 CALB2
10	cervical polyp	10.4	MYOG MME
11	myoblastoma	10.4	MYOG CALB2
12	pancreatic mucinous cystadenoma	10.4	MME CALB2
13	ovarian endometrioid stromal sarcoma	10.4	MME CALB2
14	endometriosis	10.4
15	early invasive cervical adenocarcinoma	10.4	INSM1 CDKN2A
16	inflammatory liposarcoma	10.4	MME CDKN2A
17	lymphohistiocytoid mesothelioma	10.4	CDKN2A CALB2
18	cervix endometriosis	10.4	PAX2 MME
19	vagina sarcoma	10.4	MYOG MME
20	papillary squamous carcinoma	10.3	INSM1 CDKN2A
21	lung leiomyosarcoma	10.3	MYOG CALB2
22	ovarian sex-cord stromal tumor	10.3	MME CALB2
23	atypical polypoid adenomyoma	10.3	MME CDKN2A
24	adenomyoma	10.3	MME CDKN2A
25	adult malignant schwannoma	10.3	MYOG CDKN2A
26	nasal cavity lymphoma	10.3	MME CDKN2A
27	cellular leiomyoma	10.3	MUC16 MME
28	pericardial mesothelioma	10.3	MUC16 CALB2
29	parotid gland adenoid cystic carcinoma	10.3	ERBB2 CDKN2A
30	breast metaplastic carcinoma	10.3	MME ERBB2
31	vulva basal cell carcinoma	10.3	ERBB2 CDKN2A
32	hemometra	10.3	PTPRN INSM1
33	isthmus cancer	10.3	PTPRN INSM1
34	breast malignant phyllodes tumor	10.3	MME ERBB2
35	ovary sarcoma	10.3	MME CALB2
36	microinvasive cervical squamous cell carcinoma	10.3	PTPRN INSM1
37	reproductive organ benign neoplasm	10.3	MME CDKN2A CALB2
38	heart cancer	10.3	MYOG CALB2
39	lymphocele	10.3	PTPRN INSM1
40	bleeding disorder, platelet-type, 17	10.3	PTPRN INSM1
41	malignant spiradenoma	10.3	CDKN2A CALB2
42	cystadenoma	10.3	MUC16 MME CALB2
43	vaginal cancer	10.3	MME INSM1 CDKN2A
44	epididymal neoplasm	10.3	PAX2 MME CALB2
45	kidney cortex disease	10.3	MYOG MME
46	localized osteosarcoma	10.3	ERBB2 CDKN2A
47	ovarian mesodermal adenosarcoma	10.2	PAX8 MYOG
48	rete testis neoplasm	10.2	PAX8 CALB2
49	liposarcoma	10.2	MYOG CDKN2A CALB2
50	bowenoid papulosis	10.2	CDKN2A CCNE1

Graphical network of the top 20 diseases related to Fallopian Tube Endometrioid Adenocarcinoma:

Sources

Symptoms & Phenotypes for Fallopian Tube Endometrioid Adenocarcinoma

MGI Mouse Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.1	ARID1A CCNE1 CDKN2A ERBB2 HNF1B INSM1
2	embryo	MP:0005380	9.91	ARID1A CCNE1 CDKN2A ERBB2 HNF1B MYOG
3	endocrine/exocrine gland	MP:0005379	9.9	ARID1A CCNE1 CDKN2A ERBB2 HNF1B INSM1
4	mortality/aging	MP:0010768	9.73	ARID1A CCNE1 CDKN2A ERBB2 HNF1B INSM1
5	neoplasm	MP:0002006	9.1	ARID1A CCNE1 CDKN2A ERBB2 MSH6 PMS2

Sources

Drugs & Therapeutics for Fallopian Tube Endometrioid Adenocarcinoma

Drugs for Fallopian Tube Endometrioid Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

2

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

Synonyms:

216974-75-3

antiVEGF

Anti-VEGF Humanized Monoclonal Antibody

anti-VEGF monoclonal antibody

Anti-VEGF monoclonal antibody

Avastin

Avastin (TN)

bevacizumab

Bevacizumab

Bevacizumab (genetical recombination)

Bevacizumab (genetical recombination) (JAN)

bevacizumab-awwb

D06409

R-435

rhuMAb-VEGF

3

Carboplatin

Approved

Phase 3

41575-94-4

10339178 498142 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

/q

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

4

Angiogenesis Inhibitors

Phase 3

5

Tubulin Modulators

Phase 3

6

Immunoglobulin G

Phase 3

7

Antimitotic Agents

Phase 3

8

Mitogens

Phase 3

9

Immunoglobulins, Intravenous

Phase 3

10

Albumin-Bound Paclitaxel

Phase 3

11

Immunologic Factors

Phase 3

12

Endothelial Growth Factors

Phase 3

13

Olaparib

Approved

Phase 2

763113-22-0

23725625

Synonyms:

4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one

4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one

4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one

763113-22-0

937799-91-2

Acylpiperazine analogue, 47

AKOS005145764

AZD 2281

AZD2281

AZD-2281

CHEMBL521686

EC-000.2324

EN002690

FT-0083489

KU-0059436

KU-59436

olaparib

Olaparib

Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281

S1060_Selleck

14

Ipilimumab

Approved

Phase 2

477202-00-9

15

Cediranib

Investigational

Phase 2

288383-20-0

9933475

Synonyms:

288383-20-0

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

790713-41-6

AKOS005145767

AZD 2171

AZD2171

AZD-2171

AZD2171, Recentin, Cediranib

cediranib

Cediranib

Cediranib (USAN/INN)

Cediranib maleate

CHEMBL491473

CID9933475

D08881

EC-000.2328

Kinome_3318

M6294

NSC-732208

Recentin

S1017_Selleck

UNII-NQU9IPY4K9

ZD-2171

16

Maleic acid

Experimental

Phase 2

110-16-7

444266

Synonyms:

(2Z)-2-Butenedioate

(2Z)-2-Butenedioic acid

(2Z)-But-2-enedioate

(2Z)-But-2-enedioic acid

(2Z)-Butene-2-dioate

(2Z)-Butene-2-dioic acid

(Z)-2-Butenedioate

(Z)-2-butenedioic acid

(Z)-2-Butenedioic acid

(Z)-Butenedioate

(Z)-butenedioic acid

(Z)-Butenedioic acid

2-Butenedioate

2-Butenedioic acid

cis-1,2-Ethylenedicarboxylate

cis-1,2-ethylenedicarboxylic acid

cis-1,2-Ethylenedicarboxylic acid

cis-2-Butenedioate

cis-2-Butenedioic acid

cis-But-2-enedioate

cis-but-2-enedioic acid

cis-But-2-enedioic acid

cis-Butenedioate

cis-Butenedioic acid

H2Male

Hydrogen maleate

Kyselina maleinova

MAE

Maleate

Maleic acid

Maleic acid, ammonium salt

Maleic acid, calcium salt

Maleic acid, dipotassium salt

Maleic acid, disodium salt

Maleic acid, iron salt

Maleic acid, monoammonium salt

Maleic acid, monocopper (2+) salt

Maleic acid, monosodium salt

Maleic acid, neodymium salt

Maleic acid, potassium salt

Maleic acid, sodium salt

Maleinic acid

Malenic acid

Malezid CM

Scotchbond multipurpose etchant

Sodium maleate

Toxilate

Toxilic acid

17

Tremelimumab

Investigational

Phase 2

745013-59-6

18

Maytansine

Phase 2

19

Protein Kinase Inhibitors

Phase 2

20

Antineoplastic Agents, Immunological

Phase 2

21

Antibodies

Phase 2

22

Immunoglobulins

Phase 2

23

Antibodies, Monoclonal

Phase 2

24

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
2	Life on the Go 2: Evaluating the Effect of Physical Activity of Patients With Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device	Completed	NCT03685695	Phase 2
3	A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer	Recruiting	NCT03587311	Phase 2	Paclitaxel
4	A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer	Active, not recruiting	NCT02345265	Phase 2	Cediranib Maleate;Olaparib
5	A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer	Suspended	NCT04034927	Phase 2	Olaparib

Search NIH Clinical Center for Fallopian Tube Endometrioid Adenocarcinoma

Sources

Genetic Tests for Fallopian Tube Endometrioid Adenocarcinoma

Sources

Anatomical Context for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Endometrioid Adenocarcinoma:

⁴⁰

Endothelial

Sources

Publications for Fallopian Tube Endometrioid Adenocarcinoma

Articles related to Fallopian Tube Endometrioid Adenocarcinoma:

#	Title	Authors	PMID	Year
1	Primary fallopian tube carcinoma associated with ovulation induction; a case report. ⁶¹	Deliveliotou A...Creatsas G	18217974	2008

Sources

Genes for Fallopian Tube Endometrioid Adenocarcinoma

Genes related to Fallopian Tube Endometrioid Adenocarcinoma (0 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CALB2	Calbindin 2	Protein Coding	6.31	DISEASES inferred ¹⁵
2	MME	Membrane Metalloendopeptidase	Protein Coding	5.05	DISEASES inferred ¹⁵
3	MYOG	Myogenin	Protein Coding	4.93	DISEASES inferred ¹⁵
4	EMSY	EMSY Transcriptional Repressor, BRCA2 Interacting	Protein Coding	4.65	DISEASES inferred ¹⁵
5	INSM1	INSM Transcriptional Repressor 1	Protein Coding	4.11	DISEASES inferred ¹⁵
6	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	4.09	DISEASES inferred ¹⁵
7	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	3.93	DISEASES inferred ¹⁵
8	RAD51C	RAD51 Paralog C	Protein Coding	3.92	DISEASES inferred ¹⁵
9	PAX2	Paired Box 2	Protein Coding	3.81	DISEASES inferred ¹⁵
10	HNF1B	HNF1 Homeobox B	Protein Coding	3.78	DISEASES inferred ¹⁵
11	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	3.72	DISEASES inferred ¹⁵
12	PTPRN	Protein Tyrosine Phosphatase Receptor Type N	Protein Coding	3.62	DISEASES inferred ¹⁵
13	CCNE1	Cyclin E1	Protein Coding	3.59	DISEASES inferred ¹⁵
14	PAX8	Paired Box 8	Protein Coding	3.56	DISEASES inferred ¹⁵
15	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	3.48	DISEASES inferred ¹⁵
16	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	3.34	DISEASES inferred ¹⁵
17	MSH6	MutS Homolog 6	Protein Coding	3.21	DISEASES inferred ¹⁵

Sources

Variations for Fallopian Tube Endometrioid Adenocarcinoma

Sources

Expression for Fallopian Tube Endometrioid Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Endometrioid Adenocarcinoma.

Sources

Pathways for Fallopian Tube Endometrioid Adenocarcinoma

Pathways related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.4	PAX8 MSH6 ERBB2 CDKN2A CCNE1
2	Pathways in cancer ³⁶	12.28	PAX8 MSH6 ERBB2 CDKN2A CCNE1
3	Platinum drug resistance ³⁶	11	MSH6 ERBB2 CDKN2A
4	ID signaling pathway ¹	10	PAX8 PAX2 CCNE1

Sources

GO Terms for Fallopian Tube Endometrioid Adenocarcinoma

Cellular components related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.73	RAD51C PMS2 PAX8 PAX2 MYOG MSH6
2	nucleus	GO:0005634	9.5	RAD51C PTPRN PMS2 PAX8 PAX2 MYOG
3	mismatch repair complex	GO:0032300	9.16	PMS2 MSH6

Biological processes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.08	PTPRN PAX8 PAX2 MYOG HNF1B CDKN2A
2	positive regulation of transcription, DNA-templated	GO:0045893	9.99	PAX8 PAX2 MYOG HNF1B CDKN2A ARID1A
3	positive regulation of branching involved in ureteric bud morphogenesis	GO:0090190	9.61	PAX8 PAX2
4	positive regulation of cell cycle arrest	GO:0071158	9.61	MYOG INSM1 CDKN2A
5	replicative senescence	GO:0090399	9.59	MME CDKN2A
6	urogenital system development	GO:0001655	9.58	PAX8 PAX2
7	somatic hypermutation of immunoglobulin genes	GO:0016446	9.58	PMS2 MSH6
8	mesonephros development	GO:0001823	9.57	PAX8 PAX2
9	mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0003337	9.56	PAX8 PAX2
10	regulation of metanephric nephron tubule epithelial cell differentiation	GO:0072307	9.55	PAX8 PAX2
11	metanephric epithelium development	GO:0072207	9.54	PAX8 PAX2
12	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.52	ERBB2 CDKN2A
13	metanephric nephron tubule formation	GO:0072289	9.49	PAX8 PAX2
14	metanephric distal convoluted tubule development	GO:0072221	9.48	PAX8 PAX2
15	positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0072108	9.46	PAX8 PAX2
16	positive regulation of metanephric DCT cell differentiation	GO:2000594	9.4	PAX8 PAX2
17	negative regulation of apoptotic process involved in metanephric nephron tubule development	GO:1900218	9.37	PAX8 PAX2
18	negative regulation of apoptotic process involved in metanephric collecting duct development	GO:1900215	9.32	PAX8 PAX2
19	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	9.26	PAX8 PAX2
20	negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	GO:0072305	9.16	PAX8 PAX2
21	pronephric field specification	GO:0039003	8.96	PAX8 PAX2
22	pronephros development	GO:0048793	8.8	PAX8 PAX2 HNF1B

Molecular functions related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription factor activity	GO:0003700	9.72	PAX8 PAX2 MYOG INSM1 HNF1B
2	DNA binding	GO:0003677	9.32	RAD51C PMS2 PAX8 PAX2 MYOG MSH6
3	four-way junction DNA binding	GO:0000400	9.26	RAD51C MSH6
4	mismatched DNA binding	GO:0030983	9.16	PMS2 MSH6
5	proximal promoter sequence-specific DNA binding	GO:0000987	9.13	PAX2 MYOG HNF1B

Sources

Sources for Fallopian Tube Endometrioid Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia